Franklin Resources Inc. Sells 18,484 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Franklin Resources Inc. decreased its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 233,580 shares of the company's stock after selling 18,484 shares during the period. Franklin Resources Inc. owned 0.39% of Twist Bioscience worth $10,854,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience during the third quarter valued at about $34,000. US Bancorp DE grew its position in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new position in shares of Twist Bioscience during the 3rd quarter worth about $95,000. Finally, KBC Group NV boosted its stake in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the period.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded down $0.12 during mid-day trading on Monday, reaching $38.73. 100,716 shares of the stock were exchanged, compared to its average volume of 975,202. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -11.46 and a beta of 2.34. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a 50-day simple moving average of $41.83 and a 200 day simple moving average of $44.65.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the business earned ($0.75) EPS. Twist Bioscience's revenue was up 24.1% compared to the same quarter last year. On average, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the completion of the sale, the senior vice president now directly owns 132,014 shares in the company, valued at $6,514,890.90. This trade represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Patrick John Finn sold 2,422 shares of the firm's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total transaction of $121,511.74. Following the completion of the transaction, the chief operating officer now directly owns 272,044 shares in the company, valued at $13,648,447.48. This trade represents a 0.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,796 shares of company stock worth $1,077,383 in the last 90 days. Corporate insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research analyst reports. Robert W. Baird upped their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. Barclays cut their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday. Finally, Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.